AbbVie Inc - HealthQuill

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after it scrapped development of its own weight-loss pill in April this year.

Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.

by HealthQuill
September 22, 2025
0 Comments

AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to an antibody being tested for certain types of cancers and autoimmune conditions.

Drugs Health Pharma

AbbVie inks $2 billion deal with IGI, bags antibody to fight cancer

HQ Team July 10, 2025: AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to.

by HealthQuill
July 10, 2025
0 Comments

AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services and peptide-based drug discovery, for about $2.2 billion to mark its entry into the obesity treatment space.

Drugs Medical Pharma

AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market

HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.

by HealthQuill
March 4, 2025
0 Comments

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

Drugs Health Pharma

AbbVie says schizophrenic drug fails in 2 mid-stage experimental trials

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

by HealthQuill
November 11, 2024
0 Comments

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as Alzheimer’s disease, for $1.4 billion in cash.

Drugs Health Pharma

AbbVie to acquire Aliada for $1.4 billion, bags Alzheimer’s therapy

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.

by HealthQuill
October 28, 2024
0 Comments

AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to boost the North Chicago, Illinois-based company’s presence in the psychiatric and neurological disorder segment.

Drugs Health Pharma

AbbVie to acquire Cerevel for $8.7b to bolster neurological treatments

HQ Team December 7, 2023: AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to.

by HealthQuill
December 7, 2023
0 Comments

Pfizer’s last-stage experimental trials for treating multi-drug-resistant bacteria have yielded positive results, the US-based company announced.

Drugs Health Medical Pharma

Pfizer: ’Positive results’ emerge out of multi-drug-resistant trials

HQ Team June 1, 2023: Pfizer’s last-stage experimental trials for treating multi-drug-resistant bacteria have yielded positive results, the US-based company announced. The Phase.